Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-61159 in Relapsed/Refractory Adenoid Cystic Carcinoma or Colorectal Carcinoma
NCT06462183Phase 1Active, not recruiting
- Sponsor
- Rgenta Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of RGT-61159 in adenoid cystic carcinoma (ACC) and colorectal carcinoma (CRC) (9 arms), sponsored by Rgenta Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 21 days, Adverse Events and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
RGT-61159
03
Conditions
adenoid cystic carcinoma (ACC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT06462183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462183.